Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Cardiovascular Diseases | 47 | 2024 | 15638 | 2.830 |
Why?
|
Cost-Benefit Analysis | 32 | 2023 | 5532 | 2.450 |
Why?
|
Drug Costs | 11 | 2023 | 1196 | 2.230 |
Why?
|
Amyloid Neuropathies, Familial | 5 | 2024 | 180 | 2.180 |
Why?
|
Hypercholesterolemia | 9 | 2024 | 1142 | 1.850 |
Why?
|
Hypolipidemic Agents | 5 | 2023 | 609 | 1.820 |
Why?
|
Benzoxazoles | 4 | 2024 | 92 | 1.740 |
Why?
|
American Heart Association | 19 | 2024 | 1049 | 1.740 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 12 | 2024 | 3253 | 1.570 |
Why?
|
Anticholesteremic Agents | 6 | 2019 | 972 | 1.510 |
Why?
|
Primary Prevention | 9 | 2024 | 1189 | 1.470 |
Why?
|
Endocarditis | 5 | 2022 | 355 | 1.340 |
Why?
|
Heart Failure | 18 | 2024 | 11859 | 1.310 |
Why?
|
Health Expenditures | 10 | 2023 | 2391 | 1.170 |
Why?
|
Proprotein Convertases | 3 | 2016 | 95 | 1.150 |
Why?
|
Medicare | 25 | 2024 | 6880 | 1.000 |
Why?
|
Phenprocoumon | 2 | 2015 | 19 | 0.970 |
Why?
|
Acenocoumarol | 2 | 2015 | 18 | 0.970 |
Why?
|
Hyperlipoproteinemia Type II | 5 | 2024 | 398 | 0.960 |
Why?
|
Antihypertensive Agents | 8 | 2024 | 2028 | 0.930 |
Why?
|
Quality-Adjusted Life Years | 12 | 2022 | 1734 | 0.930 |
Why?
|
Acute Coronary Syndrome | 6 | 2021 | 2195 | 0.910 |
Why?
|
Dyslipidemias | 2 | 2023 | 874 | 0.910 |
Why?
|
Specialty Boards | 2 | 2016 | 236 | 0.890 |
Why?
|
Inflation, Economic | 1 | 2023 | 30 | 0.890 |
Why?
|
Ticlopidine | 4 | 2015 | 730 | 0.850 |
Why?
|
United States | 74 | 2024 | 73120 | 0.840 |
Why?
|
Hypertension | 12 | 2024 | 8610 | 0.810 |
Why?
|
Cholesterol, LDL | 9 | 2024 | 2396 | 0.790 |
Why?
|
Cost of Illness | 4 | 2024 | 1960 | 0.780 |
Why?
|
Atherosclerosis | 8 | 2024 | 3431 | 0.780 |
Why?
|
Endocarditis, Bacterial | 2 | 2022 | 438 | 0.750 |
Why?
|
Aortic Valve Stenosis | 7 | 2023 | 2031 | 0.690 |
Why?
|
Costs and Cost Analysis | 2 | 2016 | 1670 | 0.680 |
Why?
|
Humans | 169 | 2024 | 768369 | 0.680 |
Why?
|
Vital Signs | 1 | 2021 | 144 | 0.680 |
Why?
|
Diabetes Mellitus | 7 | 2024 | 5887 | 0.660 |
Why?
|
Coronary Disease | 11 | 2024 | 5926 | 0.660 |
Why?
|
Health Care Costs | 7 | 2024 | 3266 | 0.660 |
Why?
|
Platelet Aggregation Inhibitors | 4 | 2015 | 2768 | 0.650 |
Why?
|
Rare Diseases | 1 | 2024 | 630 | 0.630 |
Why?
|
Pericarditis | 1 | 2020 | 136 | 0.630 |
Why?
|
Internal Medicine | 2 | 2016 | 1056 | 0.610 |
Why?
|
Blood Pressure | 9 | 2024 | 8537 | 0.600 |
Why?
|
Forecasting | 2 | 2024 | 2950 | 0.600 |
Why?
|
Stroke | 11 | 2024 | 9790 | 0.590 |
Why?
|
Cardiomyopathies | 2 | 2020 | 2056 | 0.590 |
Why?
|
Climate Change | 1 | 2024 | 508 | 0.580 |
Why?
|
Postoperative Hemorrhage | 3 | 2023 | 420 | 0.560 |
Why?
|
Ownership | 1 | 2019 | 343 | 0.550 |
Why?
|
Warfarin | 3 | 2021 | 1493 | 0.550 |
Why?
|
Glucosides | 1 | 2021 | 532 | 0.530 |
Why?
|
Cardiovascular Agents | 2 | 2024 | 849 | 0.530 |
Why?
|
Atrial Fibrillation | 6 | 2023 | 5162 | 0.520 |
Why?
|
Health Services | 1 | 2021 | 756 | 0.520 |
Why?
|
Policy Making | 1 | 2019 | 545 | 0.510 |
Why?
|
Heart Valve Prosthesis Implantation | 5 | 2024 | 1569 | 0.510 |
Why?
|
Ventricular Dysfunction, Left | 2 | 2023 | 2145 | 0.500 |
Why?
|
Computers, Handheld | 1 | 2017 | 211 | 0.500 |
Why?
|
Medicare Part D | 4 | 2023 | 358 | 0.490 |
Why?
|
Coronary Artery Bypass | 6 | 2022 | 2194 | 0.490 |
Why?
|
Health Status Disparities | 3 | 2021 | 1876 | 0.490 |
Why?
|
Secondary Prevention | 6 | 2024 | 1479 | 0.480 |
Why?
|
Antibodies, Monoclonal | 5 | 2017 | 9261 | 0.480 |
Why?
|
Stroke Volume | 5 | 2023 | 5620 | 0.480 |
Why?
|
Protease Inhibitors | 1 | 2018 | 753 | 0.460 |
Why?
|
Benzhydryl Compounds | 1 | 2021 | 939 | 0.460 |
Why?
|
Randomized Controlled Trials as Topic | 6 | 2023 | 10358 | 0.440 |
Why?
|
Anti-Bacterial Agents | 3 | 2023 | 7467 | 0.440 |
Why?
|
Anticoagulants | 6 | 2023 | 4835 | 0.430 |
Why?
|
Adenosine | 2 | 2015 | 816 | 0.420 |
Why?
|
Coronary Artery Disease | 8 | 2024 | 6549 | 0.410 |
Why?
|
Genotype | 4 | 2023 | 13045 | 0.400 |
Why?
|
Defibrillators, Implantable | 1 | 2022 | 1498 | 0.400 |
Why?
|
Angina Pectoris | 2 | 2016 | 960 | 0.400 |
Why?
|
Influenza, Human | 1 | 2023 | 1540 | 0.390 |
Why?
|
Aged | 49 | 2024 | 171514 | 0.390 |
Why?
|
Nutrition Surveys | 7 | 2024 | 1734 | 0.390 |
Why?
|
Public Facilities | 1 | 2011 | 35 | 0.380 |
Why?
|
Respiratory Insufficiency | 1 | 2020 | 1244 | 0.380 |
Why?
|
Cardiology | 4 | 2023 | 1701 | 0.370 |
Why?
|
Environmental Exposure | 2 | 2024 | 4533 | 0.370 |
Why?
|
Cost Sharing | 3 | 2020 | 409 | 0.360 |
Why?
|
Drug Therapy, Combination | 6 | 2023 | 6320 | 0.360 |
Why?
|
Mass Screening | 3 | 2023 | 5455 | 0.360 |
Why?
|
Cardiovascular System | 1 | 2018 | 838 | 0.350 |
Why?
|
Myocardial Infarction | 8 | 2024 | 11515 | 0.340 |
Why?
|
Heart Diseases | 4 | 2024 | 2816 | 0.340 |
Why?
|
Risk Assessment | 7 | 2024 | 24310 | 0.330 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 2 | 2008 | 1518 | 0.330 |
Why?
|
Rheumatic Heart Disease | 2 | 2020 | 164 | 0.330 |
Why?
|
Medical Oncology | 1 | 2021 | 2347 | 0.320 |
Why?
|
Health Services Accessibility | 3 | 2023 | 5508 | 0.320 |
Why?
|
Comparative Effectiveness Research | 2 | 2013 | 712 | 0.300 |
Why?
|
HIV Infections | 7 | 2021 | 17492 | 0.300 |
Why?
|
Male | 66 | 2024 | 364761 | 0.300 |
Why?
|
Female | 70 | 2024 | 396926 | 0.300 |
Why?
|
Insulin | 1 | 2022 | 6606 | 0.300 |
Why?
|
Hemorrhage | 4 | 2023 | 3456 | 0.300 |
Why?
|
Population Surveillance | 2 | 2017 | 2601 | 0.290 |
Why?
|
Medical Informatics | 1 | 2015 | 737 | 0.290 |
Why?
|
Patient Readmission | 5 | 2023 | 3308 | 0.290 |
Why?
|
Artifacts | 1 | 2016 | 1927 | 0.280 |
Why?
|
Patient Care Planning | 1 | 2013 | 904 | 0.280 |
Why?
|
Myocardial Ischemia | 3 | 2023 | 2139 | 0.280 |
Why?
|
Anti-HIV Agents | 2 | 2021 | 4563 | 0.280 |
Why?
|
Adult | 42 | 2024 | 223528 | 0.280 |
Why?
|
Aspirin | 4 | 2023 | 3139 | 0.280 |
Why?
|
Mortality | 4 | 2021 | 2917 | 0.270 |
Why?
|
Telemedicine | 4 | 2021 | 3104 | 0.270 |
Why?
|
India | 5 | 2020 | 2323 | 0.270 |
Why?
|
Developed Countries | 2 | 2024 | 451 | 0.270 |
Why?
|
Risk Factors | 27 | 2024 | 74915 | 0.270 |
Why?
|
Middle Aged | 48 | 2024 | 223406 | 0.260 |
Why?
|
Crowding | 2 | 2017 | 144 | 0.260 |
Why?
|
Treatment Outcome | 21 | 2024 | 65408 | 0.250 |
Why?
|
Angioplasty, Balloon, Coronary | 1 | 2012 | 1724 | 0.240 |
Why?
|
Barbering | 2 | 2021 | 12 | 0.240 |
Why?
|
Algorithms | 3 | 2022 | 14157 | 0.240 |
Why?
|
Fatty Acids | 2 | 2023 | 1818 | 0.230 |
Why?
|
Drug Combinations | 3 | 2019 | 2079 | 0.230 |
Why?
|
Thiazolidinediones | 1 | 2007 | 462 | 0.230 |
Why?
|
Mitral Valve Insufficiency | 2 | 2024 | 1414 | 0.230 |
Why?
|
Aged, 80 and over | 22 | 2024 | 59679 | 0.220 |
Why?
|
Registries | 7 | 2022 | 8372 | 0.220 |
Why?
|
Income | 2 | 2024 | 1878 | 0.220 |
Why?
|
Decision Support Techniques | 4 | 2019 | 2010 | 0.210 |
Why?
|
Minority Groups | 4 | 2024 | 1215 | 0.210 |
Why?
|
Practice Guidelines as Topic | 8 | 2024 | 7449 | 0.210 |
Why?
|
Lipids | 3 | 2023 | 3346 | 0.210 |
Why?
|
Serine Endopeptidases | 3 | 2016 | 1032 | 0.210 |
Why?
|
Delivery of Health Care | 3 | 2017 | 5367 | 0.210 |
Why?
|
Aftercare | 3 | 2023 | 921 | 0.210 |
Why?
|
Tetrazoles | 2 | 2019 | 922 | 0.210 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3116 | 0.200 |
Why?
|
Angina, Unstable | 2 | 2019 | 893 | 0.200 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3240 | 0.200 |
Why?
|
Aortic Valve | 5 | 2023 | 1967 | 0.200 |
Why?
|
Pharmacists | 2 | 2021 | 261 | 0.200 |
Why?
|
Viridans Streptococci | 1 | 2021 | 16 | 0.190 |
Why?
|
Hypoglycemic Agents | 2 | 2020 | 3111 | 0.190 |
Why?
|
Healthcare Disparities | 3 | 2022 | 3412 | 0.190 |
Why?
|
Rehabilitation Centers | 1 | 2023 | 250 | 0.190 |
Why?
|
Substance-Related Disorders | 3 | 2023 | 4453 | 0.190 |
Why?
|
Subtilisins | 1 | 2021 | 79 | 0.180 |
Why?
|
Dicarboxylic Acids | 1 | 2021 | 75 | 0.180 |
Why?
|
Pandemics | 6 | 2023 | 8751 | 0.180 |
Why?
|
Eligibility Determination | 1 | 2024 | 420 | 0.180 |
Why?
|
Ozone | 1 | 2024 | 490 | 0.180 |
Why?
|
Disaster Planning | 1 | 2006 | 560 | 0.180 |
Why?
|
Disasters | 1 | 2006 | 522 | 0.180 |
Why?
|
Electronics | 1 | 2022 | 318 | 0.180 |
Why?
|
Antibiotic Prophylaxis | 2 | 2022 | 640 | 0.170 |
Why?
|
Cocaine-Related Disorders | 1 | 2023 | 461 | 0.170 |
Why?
|
Cohort Studies | 11 | 2024 | 41782 | 0.170 |
Why?
|
Hospitals, Rural | 1 | 2022 | 176 | 0.170 |
Why?
|
Computer Simulation | 3 | 2019 | 6278 | 0.170 |
Why?
|
California | 3 | 2019 | 1444 | 0.170 |
Why?
|
Hospitals, Urban | 1 | 2022 | 501 | 0.170 |
Why?
|
Markov Chains | 2 | 2021 | 977 | 0.170 |
Why?
|
Housing | 2 | 2023 | 679 | 0.160 |
Why?
|
Dental Care | 1 | 2022 | 285 | 0.160 |
Why?
|
Rural Health | 1 | 2021 | 300 | 0.160 |
Why?
|
Catheter Ablation | 1 | 2013 | 2775 | 0.160 |
Why?
|
Medicaid | 3 | 2022 | 2843 | 0.160 |
Why?
|
Marketing | 1 | 2021 | 224 | 0.160 |
Why?
|
Quality of Life | 2 | 2020 | 13497 | 0.160 |
Why?
|
Budgets | 1 | 2020 | 232 | 0.160 |
Why?
|
Adrenergic beta-Antagonists | 2 | 2014 | 1244 | 0.160 |
Why?
|
Hyperlipidemias | 1 | 2023 | 773 | 0.160 |
Why?
|
Prescriptions | 1 | 2021 | 387 | 0.150 |
Why?
|
Prealbumin | 1 | 2020 | 259 | 0.150 |
Why?
|
Protective Devices | 1 | 2018 | 72 | 0.150 |
Why?
|
Urban Health | 1 | 2021 | 535 | 0.150 |
Why?
|
Tricuspid Valve Insufficiency | 1 | 2022 | 362 | 0.150 |
Why?
|
Prisoners | 1 | 2022 | 317 | 0.150 |
Why?
|
Cocaine | 1 | 2023 | 960 | 0.150 |
Why?
|
Cholesterol, HDL | 1 | 2005 | 1820 | 0.150 |
Why?
|
Aerospace Medicine | 1 | 2018 | 95 | 0.150 |
Why?
|
Models, Statistical | 5 | 2020 | 5103 | 0.150 |
Why?
|
Retrospective Studies | 19 | 2023 | 81835 | 0.150 |
Why?
|
Nitroglycerin | 1 | 2019 | 332 | 0.150 |
Why?
|
Holidays | 1 | 2017 | 41 | 0.150 |
Why?
|
Patient Discharge | 4 | 2023 | 3471 | 0.140 |
Why?
|
Economics, Medical | 1 | 2017 | 112 | 0.140 |
Why?
|
Common Cold | 1 | 2017 | 63 | 0.140 |
Why?
|
Brain Ischemia | 2 | 2022 | 3038 | 0.140 |
Why?
|
Hinduism | 1 | 2016 | 14 | 0.140 |
Why?
|
Mexico | 1 | 2019 | 766 | 0.140 |
Why?
|
Legislation, Drug | 1 | 2019 | 216 | 0.140 |
Why?
|
Death, Sudden | 1 | 2018 | 301 | 0.140 |
Why?
|
State Government | 1 | 2019 | 389 | 0.130 |
Why?
|
Mucocutaneous Lymph Node Syndrome | 1 | 2021 | 540 | 0.130 |
Why?
|
Hospital Costs | 2 | 2020 | 959 | 0.130 |
Why?
|
Nigeria | 1 | 2019 | 777 | 0.130 |
Why?
|
Nebulizers and Vaporizers | 1 | 2017 | 139 | 0.130 |
Why?
|
Mitral Valve | 1 | 2024 | 1473 | 0.130 |
Why?
|
Biphenyl Compounds | 2 | 2019 | 1026 | 0.130 |
Why?
|
Epidemics | 2 | 2019 | 517 | 0.130 |
Why?
|
Heart Valve Prosthesis | 2 | 2022 | 1468 | 0.130 |
Why?
|
Troponin I | 1 | 2020 | 662 | 0.130 |
Why?
|
Rural Population | 3 | 2022 | 2317 | 0.130 |
Why?
|
Shock, Cardiogenic | 1 | 2021 | 711 | 0.130 |
Why?
|
Thrombocytopenia | 1 | 2023 | 1183 | 0.130 |
Why?
|
Cross-Sectional Studies | 8 | 2024 | 26348 | 0.130 |
Why?
|
Prescription Drugs | 1 | 2023 | 634 | 0.130 |
Why?
|
Follow-Up Studies | 9 | 2022 | 39429 | 0.130 |
Why?
|
Adrenergic beta-Agonists | 1 | 2017 | 347 | 0.130 |
Why?
|
United States Department of Veterans Affairs | 1 | 2020 | 937 | 0.120 |
Why?
|
Patient Acceptance of Health Care | 2 | 2019 | 3237 | 0.120 |
Why?
|
Data Mining | 1 | 2020 | 561 | 0.120 |
Why?
|
Cause of Death | 4 | 2021 | 3727 | 0.120 |
Why?
|
Education, Medical, Continuing | 1 | 2020 | 829 | 0.120 |
Why?
|
Troponin T | 1 | 2020 | 787 | 0.120 |
Why?
|
Electrocardiography | 3 | 2021 | 6410 | 0.120 |
Why?
|
Myocardial Revascularization | 1 | 2019 | 796 | 0.120 |
Why?
|
Marijuana Abuse | 1 | 2019 | 412 | 0.120 |
Why?
|
Clinical Laboratory Techniques | 1 | 2020 | 749 | 0.120 |
Why?
|
Medical Audit | 1 | 2016 | 454 | 0.120 |
Why?
|
Prevalence | 6 | 2024 | 15879 | 0.120 |
Why?
|
Smoking | 1 | 2011 | 9099 | 0.120 |
Why?
|
Dogs | 1 | 2019 | 3847 | 0.120 |
Why?
|
Hospital Mortality | 4 | 2022 | 5371 | 0.120 |
Why?
|
Reimbursement Mechanisms | 1 | 2020 | 677 | 0.120 |
Why?
|
Neoplasms | 2 | 2021 | 22389 | 0.120 |
Why?
|
Employment | 1 | 2021 | 1120 | 0.120 |
Why?
|
Public Health Practice | 1 | 2016 | 221 | 0.120 |
Why?
|
Cerebrovascular Disorders | 1 | 2021 | 1487 | 0.110 |
Why?
|
Direct Service Costs | 1 | 2014 | 61 | 0.110 |
Why?
|
South Africa | 1 | 2019 | 1870 | 0.110 |
Why?
|
Outpatients | 1 | 2022 | 1607 | 0.110 |
Why?
|
Drugs, Generic | 2 | 2021 | 454 | 0.110 |
Why?
|
Clinical Trials as Topic | 4 | 2021 | 8051 | 0.110 |
Why?
|
Cough | 1 | 2017 | 598 | 0.110 |
Why?
|
China | 1 | 2019 | 2397 | 0.110 |
Why?
|
Reminder Systems | 1 | 2016 | 386 | 0.110 |
Why?
|
Bayes Theorem | 1 | 2021 | 2359 | 0.110 |
Why?
|
Urinary Tract Infections | 1 | 2019 | 806 | 0.100 |
Why?
|
Arthroplasty, Replacement, Knee | 1 | 2023 | 1401 | 0.100 |
Why?
|
Patient Transfer | 1 | 2020 | 796 | 0.100 |
Why?
|
Heart Rate | 2 | 2014 | 4218 | 0.100 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 1 | 2014 | 246 | 0.100 |
Why?
|
Drug Administration Schedule | 3 | 2021 | 4861 | 0.100 |
Why?
|
Proliferating Cell Nuclear Antigen | 2 | 2023 | 287 | 0.100 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2019 | 1066 | 0.100 |
Why?
|
Medically Underserved Area | 1 | 2015 | 266 | 0.100 |
Why?
|
Young Adult | 12 | 2024 | 60038 | 0.100 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2021 | 1898 | 0.100 |
Why?
|
Walking | 1 | 2019 | 1202 | 0.100 |
Why?
|
Life Style | 3 | 2021 | 3929 | 0.100 |
Why?
|
RNA, Small Interfering | 1 | 2021 | 3436 | 0.100 |
Why?
|
Child Mortality | 1 | 2014 | 204 | 0.100 |
Why?
|
Medication Therapy Management | 1 | 2013 | 131 | 0.100 |
Why?
|
Health Services Needs and Demand | 2 | 2021 | 1408 | 0.090 |
Why?
|
Social Class | 1 | 2020 | 2000 | 0.090 |
Why?
|
Uncertainty | 1 | 2016 | 758 | 0.090 |
Why?
|
Age Factors | 5 | 2020 | 18477 | 0.090 |
Why?
|
Maternal Mortality | 1 | 2014 | 305 | 0.090 |
Why?
|
Insurance Coverage | 2 | 2019 | 1946 | 0.090 |
Why?
|
Coronary Thrombosis | 1 | 2014 | 440 | 0.090 |
Why?
|
Pneumonia | 2 | 2019 | 2162 | 0.090 |
Why?
|
Drug Prescriptions | 2 | 2017 | 1677 | 0.090 |
Why?
|
Diarrhea | 1 | 2017 | 1320 | 0.090 |
Why?
|
Venous Thromboembolism | 1 | 2023 | 1881 | 0.090 |
Why?
|
Air Pollution | 1 | 2024 | 2364 | 0.090 |
Why?
|
Tachycardia, Ectopic Atrial | 1 | 2010 | 65 | 0.090 |
Why?
|
Quality Indicators, Health Care | 1 | 2020 | 1813 | 0.090 |
Why?
|
Heart | 1 | 2023 | 4451 | 0.080 |
Why?
|
Hospitals | 1 | 2023 | 3906 | 0.080 |
Why?
|
Fever | 1 | 2017 | 1622 | 0.080 |
Why?
|
Time Factors | 9 | 2024 | 40271 | 0.080 |
Why?
|
Thrombosis | 1 | 2023 | 2954 | 0.080 |
Why?
|
Natural Language Processing | 1 | 2018 | 1197 | 0.080 |
Why?
|
User-Computer Interface | 1 | 2016 | 1398 | 0.080 |
Why?
|
Thiophenes | 1 | 2014 | 570 | 0.080 |
Why?
|
Health Resources | 1 | 2016 | 950 | 0.080 |
Why?
|
Models, Cardiovascular | 1 | 2015 | 986 | 0.080 |
Why?
|
Infant Mortality | 1 | 2014 | 756 | 0.080 |
Why?
|
Cardiac Complexes, Premature | 1 | 2008 | 63 | 0.080 |
Why?
|
Stents | 1 | 2021 | 3204 | 0.080 |
Why?
|
Coronary Vessels | 1 | 2020 | 3123 | 0.080 |
Why?
|
Metabolic Diseases | 1 | 2015 | 685 | 0.080 |
Why?
|
Guidelines as Topic | 1 | 2015 | 1395 | 0.080 |
Why?
|
World Health Organization | 1 | 2014 | 1327 | 0.080 |
Why?
|
Heart Ventricles | 1 | 2020 | 3839 | 0.080 |
Why?
|
Coronary Angiography | 1 | 2020 | 4526 | 0.080 |
Why?
|
Ambulatory Care | 2 | 2016 | 2780 | 0.080 |
Why?
|
Organizational Objectives | 3 | 2014 | 427 | 0.070 |
Why?
|
Adolescent | 10 | 2021 | 89163 | 0.070 |
Why?
|
Calcium | 2 | 2020 | 5793 | 0.070 |
Why?
|
Adrenal Cortex Hormones | 1 | 2017 | 1891 | 0.070 |
Why?
|
Incidence | 8 | 2021 | 21552 | 0.070 |
Why?
|
Patient Compliance | 1 | 2017 | 2696 | 0.070 |
Why?
|
Occupational Diseases | 1 | 2015 | 1494 | 0.070 |
Why?
|
Patient Selection | 2 | 2013 | 4266 | 0.070 |
Why?
|
Prospective Studies | 7 | 2024 | 54913 | 0.070 |
Why?
|
Louisiana | 1 | 2006 | 104 | 0.070 |
Why?
|
Cardiac Resynchronization Therapy | 1 | 2013 | 559 | 0.070 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2021 | 4049 | 0.070 |
Why?
|
Internship and Residency | 1 | 2006 | 5952 | 0.070 |
Why?
|
Longitudinal Studies | 3 | 2020 | 14766 | 0.070 |
Why?
|
Prognosis | 6 | 2022 | 30031 | 0.070 |
Why?
|
Blood Pressure Determination | 2 | 2020 | 646 | 0.060 |
Why?
|
Ultrasonography | 1 | 2019 | 5994 | 0.060 |
Why?
|
Wounds and Injuries | 1 | 2018 | 2518 | 0.060 |
Why?
|
Sanitation | 2 | 2016 | 83 | 0.060 |
Why?
|
Critical Illness | 1 | 2018 | 2754 | 0.060 |
Why?
|
Uganda | 2 | 2021 | 1350 | 0.060 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2010 | 712 | 0.060 |
Why?
|
Texas | 1 | 2006 | 405 | 0.060 |
Why?
|
Acute Disease | 1 | 2016 | 7245 | 0.060 |
Why?
|
Developing Countries | 2 | 2015 | 2901 | 0.060 |
Why?
|
Research Design | 1 | 2021 | 6217 | 0.060 |
Why?
|
Health Policy | 1 | 2017 | 2699 | 0.060 |
Why?
|
Child | 6 | 2023 | 80856 | 0.060 |
Why?
|
Diagnosis, Differential | 1 | 2020 | 13025 | 0.060 |
Why?
|
Altruism | 1 | 2006 | 212 | 0.060 |
Why?
|
Echocardiography | 3 | 2022 | 5043 | 0.060 |
Why?
|
Lung | 2 | 2020 | 10090 | 0.060 |
Why?
|
Age Distribution | 3 | 2015 | 2881 | 0.060 |
Why?
|
Malaria | 1 | 2014 | 1240 | 0.060 |
Why?
|
Narration | 1 | 2006 | 221 | 0.060 |
Why?
|
Body Mass Index | 1 | 2022 | 13030 | 0.060 |
Why?
|
Renal Insufficiency, Chronic | 2 | 2020 | 2291 | 0.060 |
Why?
|
Hospitalization | 5 | 2021 | 10845 | 0.050 |
Why?
|
Electronic Health Records | 2 | 2018 | 4877 | 0.050 |
Why?
|
Apolipoprotein A-I | 1 | 2005 | 305 | 0.050 |
Why?
|
Drug Evaluation | 1 | 2005 | 642 | 0.050 |
Why?
|
Polymorphism, Genetic | 1 | 2014 | 4247 | 0.050 |
Why?
|
Length of Stay | 3 | 2024 | 6521 | 0.050 |
Why?
|
Piperazines | 1 | 2014 | 2546 | 0.050 |
Why?
|
Quality of Health Care | 2 | 2016 | 4340 | 0.050 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2007 | 12242 | 0.050 |
Why?
|
Physician-Patient Relations | 1 | 2016 | 3267 | 0.050 |
Why?
|
Alleles | 1 | 2014 | 6880 | 0.050 |
Why?
|
Product Surveillance, Postmarketing | 1 | 2007 | 462 | 0.050 |
Why?
|
Health Services Research | 2 | 2020 | 1815 | 0.050 |
Why?
|
American Dental Association | 1 | 2021 | 15 | 0.050 |
Why?
|
Meta-Analysis as Topic | 1 | 2007 | 1364 | 0.050 |
Why?
|
Sex Factors | 3 | 2019 | 10647 | 0.050 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2017 | 3246 | 0.050 |
Why?
|
Heroin | 1 | 2022 | 120 | 0.050 |
Why?
|
Empathy | 1 | 2006 | 476 | 0.050 |
Why?
|
Communication | 1 | 2016 | 3910 | 0.050 |
Why?
|
Severity of Illness Index | 2 | 2018 | 15965 | 0.050 |
Why?
|
Tuberculosis | 1 | 2014 | 2029 | 0.050 |
Why?
|
Oligonucleotides | 1 | 2024 | 564 | 0.050 |
Why?
|
Penicillin G Benzathine | 1 | 2020 | 25 | 0.050 |
Why?
|
Monte Carlo Method | 2 | 2017 | 1262 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2020 | 10784 | 0.040 |
Why?
|
Renin-Angiotensin System | 1 | 2005 | 735 | 0.040 |
Why?
|
Medication Adherence | 3 | 2017 | 2190 | 0.040 |
Why?
|
Kidney Failure, Chronic | 1 | 2012 | 2489 | 0.040 |
Why?
|
Schools, Medical | 1 | 2006 | 881 | 0.040 |
Why?
|
Prisons | 1 | 2022 | 178 | 0.040 |
Why?
|
Sex Distribution | 2 | 2015 | 2286 | 0.040 |
Why?
|
Clinical Competence | 1 | 2015 | 4841 | 0.040 |
Why?
|
Risk | 2 | 2021 | 9642 | 0.040 |
Why?
|
Accidents, Aviation | 1 | 2018 | 15 | 0.040 |
Why?
|
Colorado | 1 | 2019 | 166 | 0.040 |
Why?
|
Heart Transplantation | 1 | 2013 | 3291 | 0.040 |
Why?
|
Florida | 1 | 2020 | 430 | 0.040 |
Why?
|
Wit and Humor as Topic | 1 | 2018 | 31 | 0.040 |
Why?
|
Pentoxifylline | 1 | 1999 | 53 | 0.040 |
Why?
|
United States Food and Drug Administration | 1 | 2007 | 1669 | 0.040 |
Why?
|
Poverty | 2 | 2021 | 2719 | 0.040 |
Why?
|
Health Behavior | 2 | 2024 | 2649 | 0.040 |
Why?
|
Genetic Testing | 2 | 2022 | 3586 | 0.040 |
Why?
|
History, 21st Century | 1 | 2024 | 1575 | 0.040 |
Why?
|
Home Care Services | 1 | 2024 | 655 | 0.040 |
Why?
|
Hypercalcemia | 1 | 2001 | 423 | 0.040 |
Why?
|
Sodium Channel Blockers | 1 | 2019 | 173 | 0.040 |
Why?
|
Phosphodiesterase Inhibitors | 1 | 1999 | 213 | 0.040 |
Why?
|
International Cooperation | 1 | 2024 | 1439 | 0.040 |
Why?
|
New York | 1 | 2020 | 881 | 0.040 |
Why?
|
Aircraft | 1 | 2018 | 135 | 0.040 |
Why?
|
Obesity | 3 | 2024 | 13065 | 0.040 |
Why?
|
Models, Economic | 1 | 2021 | 717 | 0.030 |
Why?
|
Kenya | 1 | 2020 | 757 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2020 | 20763 | 0.030 |
Why?
|
History, 20th Century | 1 | 2024 | 2772 | 0.030 |
Why?
|
Macrophages, Alveolar | 1 | 1999 | 415 | 0.030 |
Why?
|
Probability | 1 | 2021 | 2483 | 0.030 |
Why?
|
Bioprosthesis | 1 | 2020 | 592 | 0.030 |
Why?
|
Health Planning Organizations | 1 | 2015 | 13 | 0.030 |
Why?
|
Vesico-Ureteral Reflux | 1 | 2019 | 433 | 0.030 |
Why?
|
Diagnosis | 1 | 2016 | 156 | 0.030 |
Why?
|
Delayed-Action Preparations | 1 | 2019 | 969 | 0.030 |
Why?
|
Injury Severity Score | 1 | 2018 | 1053 | 0.030 |
Why?
|
Ventricular Remodeling | 1 | 2022 | 1280 | 0.030 |
Why?
|
Child, Preschool | 4 | 2021 | 42620 | 0.030 |
Why?
|
Reproducibility of Results | 3 | 2020 | 20232 | 0.030 |
Why?
|
Gross Domestic Product | 1 | 2014 | 77 | 0.030 |
Why?
|
International Classification of Diseases | 1 | 2020 | 925 | 0.030 |
Why?
|
Vasodilator Agents | 1 | 2019 | 991 | 0.030 |
Why?
|
Lactic Acid | 1 | 1999 | 1140 | 0.030 |
Why?
|
Insecticide-Treated Bednets | 1 | 2014 | 70 | 0.030 |
Why?
|
Tuberculosis, Pulmonary | 1 | 2001 | 846 | 0.030 |
Why?
|
Survival Rate | 2 | 2022 | 12875 | 0.030 |
Why?
|
Urban Population | 1 | 2022 | 2047 | 0.030 |
Why?
|
Ambulatory Care Facilities | 1 | 2020 | 941 | 0.030 |
Why?
|
Accidents, Traffic | 1 | 2019 | 821 | 0.030 |
Why?
|
Urinary Bladder | 1 | 2019 | 1160 | 0.030 |
Why?
|
Predictive Value of Tests | 2 | 2019 | 15459 | 0.030 |
Why?
|
Health Care Surveys | 1 | 2020 | 2437 | 0.030 |
Why?
|
Thrombolytic Therapy | 1 | 2022 | 2058 | 0.030 |
Why?
|
Databases, Factual | 2 | 2020 | 8081 | 0.030 |
Why?
|
Antitubercular Agents | 1 | 2001 | 1390 | 0.030 |
Why?
|
Infant | 3 | 2021 | 36496 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 2 | 2013 | 6537 | 0.020 |
Why?
|
Syphilis | 1 | 2014 | 242 | 0.020 |
Why?
|
Safety | 1 | 2016 | 1159 | 0.020 |
Why?
|
Geriatric Assessment | 1 | 2019 | 1422 | 0.020 |
Why?
|
Animals | 2 | 2019 | 169424 | 0.020 |
Why?
|
Health Priorities | 1 | 2014 | 379 | 0.020 |
Why?
|
Blood Vessel Prosthesis Implantation | 1 | 2022 | 1460 | 0.020 |
Why?
|
Linear Models | 1 | 2021 | 5880 | 0.020 |
Why?
|
Office Visits | 1 | 2015 | 596 | 0.020 |
Why?
|
Focus Groups | 1 | 2016 | 1448 | 0.020 |
Why?
|
Socioeconomic Factors | 2 | 2014 | 7863 | 0.020 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2019 | 1189 | 0.020 |
Why?
|
Liver | 1 | 2005 | 7575 | 0.020 |
Why?
|
Refractory Period, Electrophysiological | 1 | 2008 | 40 | 0.020 |
Why?
|
Peripheral Arterial Disease | 1 | 2020 | 1299 | 0.020 |
Why?
|
Patient Satisfaction | 1 | 2021 | 3484 | 0.020 |
Why?
|
Life Expectancy | 1 | 2015 | 1249 | 0.020 |
Why?
|
Chronic Disease | 1 | 2023 | 9379 | 0.020 |
Why?
|
Alcoholism | 1 | 2019 | 1993 | 0.020 |
Why?
|
Benchmarking | 1 | 2014 | 1058 | 0.020 |
Why?
|
Disability Evaluation | 1 | 2015 | 1839 | 0.020 |
Why?
|
Infant, Newborn | 2 | 2021 | 26394 | 0.020 |
Why?
|
Disease Progression | 1 | 2005 | 13643 | 0.020 |
Why?
|
Public Health | 1 | 2021 | 2693 | 0.020 |
Why?
|
Endovascular Procedures | 1 | 2022 | 2258 | 0.020 |
Why?
|
Analgesics, Opioid | 1 | 2023 | 3837 | 0.020 |
Why?
|
Massachusetts | 1 | 2020 | 8905 | 0.020 |
Why?
|
Nutritional Status | 1 | 2015 | 1623 | 0.020 |
Why?
|
Single-Blind Method | 1 | 2010 | 1585 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2019 | 12096 | 0.020 |
Why?
|
Decision Support Systems, Clinical | 1 | 2015 | 1176 | 0.020 |
Why?
|
Guideline Adherence | 1 | 2016 | 2239 | 0.020 |
Why?
|
Diet | 1 | 2024 | 8098 | 0.020 |
Why?
|
Propensity Score | 1 | 2013 | 1970 | 0.020 |
Why?
|
Intensive Care Units | 1 | 2018 | 3804 | 0.020 |
Why?
|
Occupational Exposure | 1 | 2015 | 1818 | 0.020 |
Why?
|
Case-Control Studies | 2 | 2019 | 22286 | 0.020 |
Why?
|
Anti-Retroviral Agents | 1 | 2014 | 1792 | 0.020 |
Why?
|
Logistic Models | 1 | 2019 | 13323 | 0.010 |
Why?
|
Kidney | 1 | 2019 | 7064 | 0.010 |
Why?
|
Cytokines | 1 | 1999 | 7440 | 0.010 |
Why?
|
Disease Management | 1 | 2014 | 2533 | 0.010 |
Why?
|
Pulmonary Veins | 1 | 2008 | 755 | 0.010 |
Why?
|
Pregnancy | 2 | 2014 | 30179 | 0.010 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2014 | 2181 | 0.010 |
Why?
|
Action Potentials | 1 | 2008 | 1837 | 0.010 |
Why?
|
Greece | 1 | 2001 | 340 | 0.010 |
Why?
|
Survival Analysis | 1 | 2013 | 10127 | 0.010 |
Why?
|
Mutation | 1 | 2005 | 30235 | 0.010 |
Why?
|
Respiratory Care Units | 1 | 1999 | 10 | 0.010 |
Why?
|
Emergency Service, Hospital | 1 | 2019 | 7955 | 0.010 |
Why?
|
Depression, Chemical | 1 | 1999 | 186 | 0.010 |
Why?
|
Pyruvic Acid | 1 | 1999 | 205 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2013 | 12561 | 0.010 |
Why?
|
Comorbidity | 1 | 2013 | 10601 | 0.010 |
Why?
|
Physicians | 1 | 2016 | 4615 | 0.010 |
Why?
|
Albumins | 1 | 2001 | 578 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2020 | 15879 | 0.010 |
Why?
|
Cell Hypoxia | 1 | 1999 | 661 | 0.010 |
Why?
|
Bronchoalveolar Lavage Fluid | 1 | 1999 | 762 | 0.010 |
Why?
|
Macrophage Activation | 1 | 1999 | 556 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2010 | 14725 | 0.010 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1999 | 895 | 0.010 |
Why?
|
Interleukin-1 | 1 | 1999 | 1251 | 0.010 |
Why?
|
Leukocytes, Mononuclear | 1 | 1999 | 1852 | 0.010 |
Why?
|
Lipopolysaccharides | 1 | 1999 | 2216 | 0.010 |
Why?
|
Hemodynamics | 1 | 1999 | 4202 | 0.000 |
Why?
|
Interleukin-6 | 1 | 1999 | 3234 | 0.000 |
Why?
|
Protein Binding | 1 | 2001 | 9376 | 0.000 |
Why?
|
Lung Diseases | 1 | 1999 | 1926 | 0.000 |
Why?
|
Respiration, Artificial | 1 | 1999 | 2723 | 0.000 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 1999 | 4362 | 0.000 |
Why?
|
Cells, Cultured | 1 | 1999 | 19035 | 0.000 |
Why?
|